The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A10 | Drugs used in diabetes | |
| 3 | A10B | Blood glucose lowering drugs, excl. insulins | |
| 4 | A10BB | Sulfonamides, urea derivatives | |
| 5 | A10BB01 | Glibenclamide |
| Active Ingredient | Description | |
|---|---|---|
| Glibenclamide |
Glibenclamide, a second-generation, short half-life sulphonylurea, is a hypoglycaemic agent that reduces blood-glucose by stimulating insulin release by the pancreas. Sulphonylureas act on pancreatic beta-cells by inhibiting ATP-sensitive potassium channels. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| AMGLIDIA Oral suspension | European Medicines Agency (EU) | MPI, EU: SmPC | |
| GLIBESYN Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| GLITISOL Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
